- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01701609
Cognitive Remediation Therapy (CRT) in Adolescents With EOS
Efficacy of a Cognitive Remediation Treatment in Adolescents With Schizophrenia Spectrum Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Early-onset schizophrenia (EOS) is associated with worse course and poor outcome than adulthood schizophrenia. Cognitive deficits are known to be a core feature in EOS, with large deficits on almost all cognitive domains. Importantly, cognitive deficits are known to be strong predictors of psychosocial and functional outcomes in schizophrenia and also in the early-onset form of the illness. Cognitive Remediation Therapy (CRT) is a behavioral training based intervention that aims to improve cognitive processes (attention, memory, executive function, social cognition or metacognition) with the goal of durability and generalization. It has been demonstrated that CRT improve cognitive deficits and functional outcome in adult patients but there are very few studies with adolescent samples.
A controlled randomized study will be carry out with two groups: patients receiving treatment as usual plus CRT, and patients receiving treatment as usual (TAU). The independent variable is the cognitive remediation treatment. The CRT will be applied according to the manual of Wykes and Reeder (2005). The program has a duration of 40 sessions, with two session for week. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
The main dependent variable is the cognitive performance measured through neuropsychological tests. Other secondary dependent variables are functional outcome and clinical symptoms obtained from the psychometric evaluation.
All participants will be evaluated before and after the experimental intervention in several neurocognitive domains, clinical symptoms and functional outcome. The evaluations will be carried out by expert evaluators. Intention-to-treat analysis will be carry out using the statistical package SPSS v 18.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08036
- Department of Child and Adolescent Pyshicatry and Psychology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age between 12 and 18 years
- a DSM-IV-TR schizophrenia-type disorder (schizophrenia or schizoaffective disorder), with onset before the age of 17
- being clinically and pharmacologically stabilized during the last 6 weeks before the baseline assessment
- the estimation of not modifying pharmacological antipsychotic treatment
- presence of cognitive deficit confirmed by the neuropsychological battery
Exclusion Criteria:
- IQ below 70
- presence of an active misuse disorder
- presence of organic brain syndromes or neurological disorders
- having received electroconvulsive therapy in the previous 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive Remediation Therapy
CRT: Frontal/Executive Program.
The program has a duration of 40 sessions, with two session for week.
Is is carried out individually and utilizes paper and pencil tasks.
The main technique utilized is the scaffolding in a context of learning without errors.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive performance
Time Frame: 20 weeks
|
Change from baseline in neuropsychological test scores of memory, executive functions, working memory and processing speed at post-treatment evaluation
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional outcome
Time Frame: 20 weeks
|
Change in real-world functioning scales, self-esteem and caregiver burden at post-treatment evaluation
|
20 weeks
|
Symptoms
Time Frame: 20 weeks
|
Change from baseline in measures of clinical symptoms at post-treatment evaluation
|
20 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Olga Puig, PhD, Hospital Clinic of Barcelona
- Study Director: Rafael Penadés, PhD, Hospital Clinic of Barcelona
- Study Director: Josefina Castro-Fornieles, MD, Hospital Clinic of Barcelona
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI07/90054
- ETES07/90054 (Other Grant/Funding Number: ISCIII)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Cognitive Remediation Therapy
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Gemma Garrido GarcíaCompleted
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Mental DisordersUnited States
-
Fraser HealthMinistry of Social Development and Poverty Reduction, British ColumbiaCompletedSchizophrenia and Related Disorders | Psychotic DisorderCanada
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Cognitive Deficit | Cognitive Remediation | Functional Impairment | Late Life SchizophreniaCanada
-
King's College LondonUnknownSchizophrenia Schizoaffective
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedAnorexia NervosaUnited States
-
Hospital Clinic of BarcelonaNational Alliance for Research on Schizophrenia and Depression; Instituto de...Unknown